Andreas B. Herrmann, Martha-Lena Müller, Martin F. Orth, Jörg P. Müller, Alma Zernecke, Andreas Hochhaus, Thomas Ernst, Elke Butt, Jochen J. Frietsch: Knockout of LASP1 in CXCR4 expressing CML cells promotes cell persistence, proliferation and TKI resistance. Received: 21 November 2019. Accepted: 30 November 2019, DOI: 10.1111/jcmm.14910
Hartung S, Rauh C, Böttcher S, Hoang MTN, Jahreis S, Rummler S, Hochhaus A, von Lilienfeld-Toal M: Measuring Phagocytosis of Aspergillus fumigatus Conidia by Human Leukocytes using Flow Cytometry. J Vis Exp. 2019 Dec 7;(154). doi: 10.3791/60397. PMID: 31868176
Radivoyevitch T, Weaver D, Hobbs B, Maciejewski JP, Hehlmann R, Jiang Q, Hochhaus A, Gale RP: Do persons with chronic myeloid leukaemia have normal or near normal survival? Leukemia. 2019 Dec 20. doi: 10.1038/s41375-019-0699-y. [Epub ahead of print] PMID: 31862960
Hughes TP, Mauro MJ, Cortes JE, Minami H, Rea D, DeAngelo DJ, Breccia M, Goh YT, Talpaz M, Hochhaus A, le Coutre P, Ottmann O, Heinrich MC, Steegmann JL, Deininger MWN, Janssen JJWM, Mahon FX, Minami Y, Yeung D, Ross DM, Tallman MS, Park JH, Druker BJ, Hynds D, Duan Y1, Meille C, Hourcade-Potelleret F, Vanasse KG, Lang F, Kim DW: Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure. N Engl J Med. 2019 Dec 12;381(24):2315-2326. doi: 10.1056/NEJMoa1902328. PMID: 31826340
Brioli A, Manz K, Pfirrmann M, Hänel M, Schwarzer AC, Prange-Krex G, Fabisch C, Knop S, Illmer T, Krammer-Steiner B, Hochhaus A, von Lilienfeld-Toal M, Mügge LO: Frailty impairs the feasibility of induction therapy but not of maintenance therapy in elderly myeloma patients: final results of the German Maintenance Study (GERMAIN). J Cancer Res Clin Oncol. 2019 Dec 2. doi: 10.1007/s00432-019-03101-z. [Epub ahead of print] PMID:31788741
Büntzel, J., Hübner, J. & Büntzel, J. Komplementärmedizinische Behandlungsansätze bei Inappetenz und Ösophagitis. Onkologe (2019) 25: 1110. https://doi.org/10.1007/s00761-019-00667-8
Austin RJ, Straube J, Bruedigam C, Pali G, Jacquelin S, Vu T, Green J, Gräsel J, Lansink L, Cooper L, Lee SJ, Chen NT, Lee CW, Haque A, Heidel FH, D'Andrea R, Hill GR, Mullally A, Milsom MD, Bywater M, Lane SW: Distinct effects of ruxolitinib and interferon-alpha on murine JAK2V617F myeloproliferative neoplasm hematopoietic stem cell populations. Leukemia. 2019 Nov 15. doi: 10.1038/s41375-019-0638-y. [Epub ahead of print] PMID: 31732720
Mihajlović J, Diehl LAM, Hochhaus A, Clement JH: Inhibition of bone morphogenetic protein signaling reduces viability, growth and migratory potential of non-small cell lung carcinoma cells. J Cancer Res Clin Oncol. 2019 Nov;145(11):2675-2687. doi: 10.1007/s00432-019-03026-7. Epub 2019 Sep 17. PMID: 31531741
Franke GN, Maier J, Wildenberger K, Cross M, Giles FJ, Müller MC, Hochhaus A, Niederwieser D, Lange T: Comparison of Real-Time quantitative PCR and digital droplet PCR for BCR-ABL1 Monitoring in Patients with Chronic Myeloid Leukemia. J Mol Diagn. 2019 Oct 24. pii: S1525-1578(19)30403-9. doi: 10.1016/j.jmoldx.2019.08.007. [Epub ahead of print] PMID: 31669230
Hochhaus A, · Höffken K: Fortschritte in der Diagnostik und Therapie chronischer Leukämien und Myelodysplasien. Onkologe 2019 · 25:946–947. https://doi.org/10.1007/s00761-019-00650-3
Heidel F, · Döhner K: Risikoadaptierte Therapie chronischer BCR-ABL1-negativer myeloproliferativer Neoplasien. Onkologe 2019 · 25:985–993. https://doi.org/10.1007/s00761-019-0576-3. Online publiziert: 2. Mai 2019
Hochhaus A, · Fabisch C, · Ernst T: Therapie der chronischen myeloischen Leukämie. Onkologe 2019 ・ 25:971–984. https://doi.org/10.1007/s00761-019-0638-6. Online publiziert: 13. August 2019
Keinki C., · Freuding M, · Micke O, · Büntzel J, · Hübner J: Immunstimulanzien aus der Naturheilkunde. Onkologe 2019 · 25:1014–1019 https://doi.org/10.1007/s00761-019-0625-y Online publiziert: 19. Juli 2019
Kahl M, Brioli A, Bens M4, Perner F, Kresinsky A, Schnetzke U, Hinze A, Sbirkov Y, Stengel S, Simonetti G, Martinelli G, Petrie K, Zelent A, Böhmer FD, Groth M, Ernst T, Heidel FH, Scholl S, Hochhaus A, Schenk T: The acetyltransferase GCN5 maintains ATRA-resistance in non-APL AML. Leukemia. 2019 Oct 1. doi: 10.1038/s41375-019-0581-y. [Epub ahead of print] PMID: 31576004
Mihajlović J, Diehl LAM, Hochhaus A, Clement JH: Inhibition of bone morphogenetic protein signaling reduces viability, growth and migratory potential of non-small cell lung carcinoma cells. J Cancer Res Clin Oncol. 2019 Sep 17. doi: 10.1007/s00432-019-03026-7. [Epub ahead of print] PMID: 31531741
Lauseker M, Bachl K, Turkina A, Faber E, Prejzner W, Olsson-Strömberg U, Baccarani M, Lomaia 7, Zackova D, Ossenkoppele G, Griskevicius L, Schubert-Fritschle G, Sacha T, Heibl S, Koskenvesa P, Bogdanovic A, Clark RE, Guilhot J, Hoffmann VS, Hasford J, Hochhaus A, Pfirrmann M: Prognosis of patients with chronic myeloid leukemia presenting in advanced phase is defined mainly by blast count, but also by age, chromosomal aberrations and hemoglobin. Am J Hematol. 2019 Aug 27. doi: 10.1002/ajh.25628. [Epub ahead of print] PMID: 31456269
Hochhaus A, Ernst T: Neue Entwicklungen der Systemtherapie maligner Erkrankungen. Onkologe 2019 · 25 (Suppl 1):S68–S76, https://doi.org/10.1007/s00761-019-00648-x, Online publiziert: 13. August 2019, © Springer Medizin Verlag GmbH, ein Teil von Springer Nature 2019
Alcala N, Leblay N, Gabriel AAG, Mangiante L, Hervas D, Giffon T, Sertier AS, Ferrari A, Derks J, Ghantous A, Delhomme TM, Chabrier A, Cuenin C, Abedi-Ardekani B, Boland A, Olaso R, Meyer V, Altmuller J, Le Calvez-Kelm F, Durand G, Voegele C, Boyault S, Moonen L, Lemaitre N, Lorimier P, Toffart AC, Soltermann A, Clement JH, Saenger J, Field JK, Brevet M, Blanc-Fournier C, Galateau-Salle F, Le Stang N, Russell PA, Wright G, Sozzi G, Pastorino U, Lacomme S, Vignaud JM, Hofman V, Hofman P, Brustugun OT, Lund-Iversen M, Thomas de Montpreville V, Muscarella LA, Graziano P, Popper H, Stojsic J, Deleuze JF, Herceg Z, Viari A, Nuernberg P, Pelosi G, Dingemans AMC, Milione M, Roz L, Brcic L, Volante M, Papotti MG, Caux C, Sandoval J, Hernandez-Vargas H, Brambilla E, Speel EJM, Girard N, Lantuejoul S, McKay JD, Foll M, Fernandez-Cuesta L: Integrative and comparative genomic analyses identify clinically relevant pulmonary carcinoid groups and unveil the supra-carcinoids. Nat Commun. 2019 Aug 20;10(1):3407. doi: 10.1038/s41467-019-11276-9. PMID: 31431620
Perner F, Perner C, Ernst T, Heidel FH: Roles of JAK2 in Aging, Inflammation, Hematopoiesis and Malignant Transformation. Cells. 2019 Aug 8;8(8). pii: E854. doi: 10.3390/cells8080854. PMID: 31398915
Hochhaus A, Ernst T: Neue Entwicklungen der Systemtherapie maligner Erkrankungen. Onkologe (2019). https://doi.org/10.1007/s00761-019-00648-x
Hochhaus A, Fabisch C, Ernst T: Therapie der chronischen myeloischen Leukämie. Onkologe (2019). https://doi.org/10.1007/s00761-019-0638-6
Michel C, Burchert A, Hochhaus A, Saussele S, Neubauer A, Lauseker M, Krause SW, Kolb HJ, Hossfeld DK, Nerl C, Baerlocher GM, Heim D, Brümmendorf TH, Fabarius A, Haferlach C, Schlegelberger B, Balleisen L, Goebeler ME, Hänel M, Ho A, Dengler J, Falge C, Möhle R, Kremers S, Kneba M, Stegelmann F, Köhne CH, Lindemann HW, Waller CF, Spiekermann K, Berdel WE, Müller L, Edinger M, Mayer J, Beelen DW, Bentz M, Link H, Hertenstein B, Fuchs R, Wernli M, Schlegel F, Schlag R, de Wit M, Trümper L, Hebart H, Hahn M, Thomalla J, Scheid C, Schafhausen P, Verbeek W, Eckart MJ, Gassmann W, Schenk M, Brossart P, Wündisch T, Geer T, Bildat S, Schäfer E, Hasford J, Hehlmann R4, Pfirrmann M: Imatinib dose reduction in major molecular response of chronic myeloid leukemia: results from the German Chronic Myeloid Leukemia-Study IV. Haematologica. 2019 May;104(5):955-962. doi: 10.3324/haematol.2018.206797. Epub 2018 Dec 4. PMID: 30514803
Gebauer J, Hilgendorf I, Koch B, Langer T: Neue Strukturen in der Betreuung und Nachsorge junger Krebspatienten. Oncol Res Treat 2019;42(suppl 3):21–26, DOI: 10.1159/000500818
Hochhaus A, Burchert A, Saußele S: Absetzen der CML-Therapie – „therapiefreie Remission“. JOURNAL ONKOLOGIE, 7/8 2019
Fabisch C, Clauß C, Kolb M: Studien der Deutschen CML-Studiengruppe. JOURNAL ONKOLOGIE, 7/8 2019
Kolb M, Hochhaus A, Tesch H, Geißler J: Deutsche CML-Allianz. JOURNAL ONKOLOGIE, 7/8 2019
Linke P: Erstdiagnose chronische myeloische Leukämie. JOURNAL ONKOLOGIE, 7/8 2019
Fischer M, Hochhaus A, Ernst T: Zytogenetische und molekulare Verlaufskontrolle der CML. JOURNAL ONKOLOGIE, 7/8 2019
Hochhaus A, Ernst T: Management der CML 2019. JOURNAL ONKOLOGIE, 7/8 2019
Bartholomäus M, Zomorodbakhsch B, Micke O, Prott FJ, Rudolph I, Seilacher E, Hochhaus A, Huebner J: Cancer patients' needs for virtues and physicians' characteristics in physician-patient communication: a survey among patient representatives. Support Care Cancer. 2019 Aug;27(8):2783-2788. doi: 10.1007/s00520-018-4585-3. Epub 2018 Dec 6. PMID: 30523413
Dubois C, Eisfeld H, Bauer F, Schmidt T, Kastrati K, Hochhaus A, Hübner J: Not all cancer patients with an interest in CAM are the same. Differences between patients with a CAM interest prior to the cancer diagnosis and those with first-time interest since diagnosis. Complement Ther Med. 2019 Aug;45:167-171. doi: 10.1016/j.ctim.2019.06.009. Epub 2019 Jun 14. PMID: 31331555
Battipaglia G, Labopin M, Kröger N, Vitek A, Afanasyev B, Hilgendorf I, Schetelig J, Ganser A, Blaise D, Itälä-Remes M, Passweg JR, Bonifazi F, Finke J, Ruggeri A, Nagler A, Mohty M: Post-Transplant Cyclophosphamide versus Antithymocyte Globulin in HLA-Mismatched unrelated Donors transplantation. Blood. 2019 Jul 3. pii: blood.2019000487. doi: 10.1182/blood.2019000487. [Epub ahead of print] PMID: 31270102
Lamby P, Wolff D, Mielke S, Grigoleit GU, Ljungman P, Hilgendorf I, Holler E, Holler B, Weber D, Herr W, Schiltz D, Klein S, Graf S, Bjornhagen-Safwenberg V, Dolderer J, Prantl L: Allogeneic donor split skin grafts for treatment of refractory ulcers in cutaneous chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation-a retrospective analysis on seven patients. Ann Hematol. 2019 Aug;98(8):1867-1875. doi: 10.1007/s00277-019-03687-x. Epub 2019 Apr 16. PMID: 30993415
Wolff D, Hilgendorf I, Wagner-Drouet E, Jedlickova Z, Ayuk F, Zeiser R, Schäfer-Eckart K, Gerbitz A, Stadler M, Klein S, Middeke JM, Lawitschka A, Winkler J, Halter J, Holler E, Kobbe G, Stelljes M, Ditschkowski M, Greinix H: Changes in Immunosuppressive Treatment of Chronic Graft-versus-Host Disease: Comparison of 2 Surveys within Allogeneic Hematopoietic Stem Cell Transplant Centers in Germany, Austria, and Switzerland. Biol Blood Marrow Transplant. 2019 Jul;25(7):1450-1455. doi: 10.1016/j.bbmt.2019.03.003. Epub 2019 Mar 13. PMID: 30876928
Branford S, Kim DDH, Apperley JF, Eide CA, Mustjoki S, Ong ST, Nteliopoulos G, Ernst T, Chuah C, Gambacorti-Passerini C, Mauro MJ, Druker BJ, Kim DW, Mahon FX, Cortes J, Radich JP, Hochhaus A, Hughes TP; International CML Foundation Genomics Alliance: Laying the foundation for genomically-based risk assessment in chronic myeloid leukemia. Leukemia. 2019 Jun 17. doi: 10.1038/s41375-019-0512-y. [Epub ahead of print] PMID: 31209280
Al-Batran SE, Homann N, Pauligk C, Goetze TO, Meiler J, Kasper S, Kopp HG, Mayer F, Haag GM, Luley K, Lindig U, Schmiegel W, Pohl M, Stoehlmacher J, Folprecht G, Probst S, Prasnikar N, Fischbach W, Mahlberg R, Trojan J, Koenigsmann M, Martens UM, Thuss-Patience P, Egger M, Block A, Heinemann V, Illerhaus G, Moehler M, Schenk M, Kullmann F, Behringer DM, Heike M, Pink D, Teschendorf C, Löhr C, Bernhard H, Schuch G, Rethwisch V, von Weikersthal LF, Hartmann JT, Kneba M, Daum S, Schulmann K, Weniger J, Belle S, Gaiser T, Oduncu FS, Güntner M, Hozaeel W, Reichart A, Jäger E, Kraus T, Mönig S, Bechstein WO, Schuler M, Schmalenberg H, Hofheinz RD; FLOT4-AIO Investigators: Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. Lancet. 2019 Apr 10. pii: S0140-6736(18)32557-1. doi: 10.1016/S0140-6736(18)32557-1. [Epub ahead of print] PMID: 30982686
La Rosée P, Horne A, Hines M, von Bahr Greenwood T, Machowicz R, Berliner N, Birndt S, Gil-Herrera J, Girschikofsky M, Jordan MB, Kumar A, van Laar JA, Lachmann G, Nichols KE, Ramanan AV, Wang Y, Wang Z, Janka G, Henter JI: Recommendations for the management of hemophagocytic lymphohistiocytosis in adults. Blood. 2019 Apr 16. pii: blood.2018894618. doi: 10.1182/blood.2018894618. [Epub ahead of print] PMID: 30992265
Cortes JE, Gambacorti-Passerini C, Deininger MW, Mauro MJ, Chuah C, Kim DW, Milojkovic D, le Coutre P, Garcia-Gutierrez V, Crescenzo R, Mamolo C, Reisman A, Hochhaus A, Brümmendorf TH; BFORE Study Investigators: Patient-reported outcomes in the phase 3 BFORE trial of bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia. J Cancer Res Clin Oncol. 2019 Apr 15. doi: 10.1007/s00432-019-02894-3. [Epub ahead of print] PMID: 30989330
Ortmann O, Torode J, Harrison C, Bruns J, Helbig U; Participants of the ERTM: Research driving innovation: what are key factors for successful integration of translational science into oncology care concepts? 5th European Roundtable Meeting (ERTM) May 4th, 2018, Berlin, Germany. J Cancer Res Clin Oncol. 2019 Apr 16. doi: 10.1007/s00432-019-02916-0. [Epub ahead of print] PMID: 30993404
Möbius S, Schenk T, Himsel D, Maier J, Franke GN, Saussele S, Pott C, Andrikovics H, Meggyesi N, Machova-Polakova K, Zizkova H, Jurcek T, Mesanovic S, Zadro R, Gottardi E, Haenig J, Schuld P, Cross NCP, Hochhaus A, Ernst T: Results of the European survey on the assessment of deep molecular response in chronic phase CML patients during tyrosine kinase inhibitor therapy (EUREKA registry). J Cancer Res Clin Oncol. 2019 Apr 2. doi: 10.1007/s00432-019-02910-6. [Epub ahead of print] PMID: 30941573
Hochhaus A, Eigendorff E, Ernst T: Chronische Myeloische Leukämie. TumorDiagn u Ther 2019; 40: 43-49
Frietsch JJ, Michel D, Stamminger T, Hunstig F, Birndt S, Schnetzke U, Scholl S, Hochhaus A, Hilgendorf I: In Vivo Emergence of UL56 C325Y Cytomegalovirus Resistance to Letermovir in a Patient with Acute Myeloid Leukemia after Hematopoietic Cell Transplantation. Mediterr J Hematol Infect Dis. 2019 Jan 1;11(1):e2019001. doi: 10.4084/MJHID.2019.001. eCollection 2019. PMID: 30671207
Hüttmann A, Rekowski J, Müller SP, Hertenstein B, Franzius C, Mesters R, Weckesser M, Kroschinsky F, Kotzerke J, Ganser A, Bengel FM, La Rosée P, Freesmeyer M, Höffkes HG, Hertel A, Behringer D, Prange-Krex G, Griesshammer M, Holzinger J, Wilop S, Krohn T, Raghavachar A, Maschmeyer G, Brink I, Schroers R, Gaska T, Bernhard H, Giagounidis A, Schütte J, Dienst A, Hautzel H, Naumann R, Klein A, Hahn D, Pöpperl G, Grube M, Marienhagen J, Schwarzer A, Kurch L, Höhler T, Steiniger H, Nückel H, Südhoff T, Römer W, Brinkmann M, Ose C, Alashkar F, Schmitz C, Dürig J, Hoelzer D, Jöckel KH, Klapper W, Dührsen U: Six versus eight doses of rituximab in patients with aggressive B cell lymphoma receiving six cycles of CHOP: results from the "Positron Emission Tomography-Guided Therapy of Aggressive Non-Hodgkin Lymphomas" (PETAL) trial. Ann Hematol. 2019 Jan 4. doi: 10.1007/s00277-018-3578-0. [Epub ahead of print] PMID: 30610279
Frietsch JJ, Winkelmann N, Hunstig F, Schnetzke U, Hammersen FJ, Dönicke T, Lenz M, Gras F, Scholl S, Hochhaus A, Hilgendorf I: A Mosquito Bite with Devastating Complications in an Immunocompromised Patient. Case Rep Oncol. 2019 Jan 4;12(1):22-28. doi: 10.1159/000495878. eCollection 2019 Jan-Apr. PMID: 30792641
Brioli A, Klaus M, Sayer H, Scholl S, Ernst T, Hilgendorf I, Scherag A, Yomade O, Schilling K, Hochhaus A, Mügge LO, von Lilienfeld-Toal M: The risk of infections in multiple myeloma before and after the advent of novel agents: a 12-year survey. Ann Hematol. 2019 Jan 24. doi: 10.1007/s00277-019-03621-1. [Epub ahead of print] PMID: 30680505
Eisfeld H, Bauer F, Dubois C, Schmidt T, Kastrati K, Hochhaus A, Hübner J: Importance of and Satisfaction with Information about Their Disease in Cancer Patients. J Cancer Educ. 2019 Jan 25. doi: 10.1007/s13187-019-1480-7. [Epub ahead of print] PMID:30684231
Hübner J: Integrative Onkologie – auch eine ethische Aufgabe. Onkologe 2019 · 25:157–158 https://doi.org/10.1007/s00761-018-0509-6
P Lamby , D Wolff , S Mielke, G U Grigoleit, P Ljungman, I Hilgendorf, E Holler , B Holler, D Weber, W Herr, D Schiltz, S Klein, S Graf, V Bjornhagen-Safwenberg , J Dolderer , L Prantl: Allogeneic Donor Split Skin Grafts for Treatment of Refractory Ulcers in Cutaneous Chronic Graft-Versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation-A Retrospective Analysis on Seven Patients. Case Reports Ann Hematol. 2019 Aug;98(8):1867-1875. doi: 10.1007/s00277-019-03687-x. Epub 2019 Apr 16. PMID: 30993415
Wagner-Drouet E, Teschner D, Wolschke C, Janson D, Schäfer-Eckart K, Gärtner J, Mielke S, Schreder M, Kobbe G, Kondakci M, Hilgendorf I, von Lilienfeld-Toal M, Klein S, Heidenreich D, Kreil S, Verbeek M, Graß S, Ditschkowski M, Gromke T, Koch M, Lindemann M, Hünig T, Schmidt T, Anne Rascle A, HGuldan H, Barabas S, Deml L, Wagner R, Wolff D: Standardized Monitoring of Cytomegalovirus-Specific Immunity Can Improve Risk Stratification of Recurrent Cytomegalovirus Reactivation After Hematopoietic Stem Cell Transplantation. Haematologica. 2019 Dec 26;haematol.2019.229252. doi: 10.3324/haematol.2019.229252. Online ahead of print. PMID: 31879324
Koehler M, Mann J, Richter D, · I. Hilgendorf K: Krebs bei Jugendlichen und jungen Erwachsenen Status quo der interdisziplinären Versorgung in Deutschland. Forum https://doi.org/10.1007/s12312-019-00724-8, published online 3 December 2019
Gräfe C, von der Lühe M, Weidner A, Globig P, Clement JH, Dutz S, Schacher FH: Protein corona formation and its constitutional changes on magnetic nanoparticles in serum featuring a polydehydroalanine coating: effects of charge and incubation conditions. Nanotechnology. 2019;30(26):265707. doi:10.1088/1361-6528/ab0ed0, PMID: 30861506